more_reports

DarioHealth AI Platform Targets 10-15% Revenue Growth from Existing Clients

  ()
DarioHealth's DarioIQ AI engine is positioned to lift B2B2C recurring revenue 10-15% from current customers while the AI healthcare market expands rapidly toward hundreds of billions.

AI Engine Delivers Engagement Gains as Recurring Revenue Outlook Climbs

  ()
DarioHealth Corp. (DRIO:NASDAQ) said its DarioIQ platform reflects the ongoing digital health rotation and AI transformation across healthcare, with broader deployment expected to increase recurring revenue from existing customers by 10% to 15%.

Pet Odor Market Ignites BioLargo Consumer Comeback

  ()
BioLargo re-enters the booming U.S. pet odor control market with a direct-to-consumer CupriDyne brand, building on proven demand while advancing water treatment and medical technologies for retail investors.

Cleantech Co. Relaunches Pet Brand Under Its Own Control

  ()
BioLargo Inc. (BLGO:OTCQX) unveils plans to reintroduce its enormously popular CupriDyne-based pet odor products to the consumer market. This time, the company says it will own the brand and do it its own way.

Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win

  ()
Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity.

Biotech With Muscle Disease Drug Uncovers Results in Trial Data

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.

Digital Health Platform Lands Access to Hundreds of Thousands of Covered Lives

  ()
DarioHealth Corp. (DRIO:NASDAQ) signed a new agreement through its Amwell partnership that makes its cardiometabolic platform available to a major Arizona health insurer's ASO business, representing hundreds of thousands of covered lives.

NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss

Research Report
  ()
The FDA accepted the company's morpholino oligomer filings with a February 2027 PDUFA date, but a missed confirmatory trial endpoint clouds its path to full approval.

Grey Matters Health Inc. Targets Alzheimer's PET Imaging Opportunity

  ()
Grey Matters Health Inc. advances first U.S. brain-dedicated PET clinic for Alzheimer's detection amid surging diagnostics demand. Learn the key facts for investors.

BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew

  ()
BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.

First-of-Its-Kind US Brain Imaging Clinic Takes Delivery of Key PET Scanner

  ()
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) received its first brain-dedicated PET scanning system for its flagship Florida NovaScan Neuroimaging Clinic, which the company said will be the first U.S. facility dedicated to brain-only PET imaging for Alzheimer's disease and other neurological conditions.

Air Force Bases Renew Their Contracts With Cleantech Pioneer

  ()
Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) says its engineering division has secured contract renewals worth over US$1.4 million. Find out why experts like this technology incubator's structure.

French Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing

Research Report
  ()
A Wedbush analyst raised its target on a French biopharma's ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn's readout.

Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst

  ()
Abivax SA (ABVX) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late 2026. Learn why this oral miR-124 therapy stands out for investors now.

How Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases?

  ()
Find out what analysts think of clinical-stage biotech Abivax SA (ABVX:NASDAQ), which is focusing on harnessing the immune response in patients with chronic inflammatory diseases.

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Satellos Bioscience Fast Track Win Fuels DMD Hopes

  ()
Satellos Bioscience earns FDA Fast Track for SAT-3247 in Duchenne. Explore the market opportunity, clinical catalysts, analyst targets, and what retail investors should know now.

Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) earns FDA Fast Track designation for its Duchenne treatment SAT-3247, positioning the company for potential breakthrough gains.

Abivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunity

  ()
Abivax SA (ABVX:NASDAQ) reports strong obefazimod maintenance results in ulcerative colitis. Explore sector growth, analyst targets, catalysts, and what it means for investors.

Clinical-Stage Biotech Discloses Colitis Retreatment Results, Gets Mixed Ratings

  ()
Abivax SA (ABVX:NASDAQ) reports 69.7% clinical response and 45.0% remission rates in relapsed UC patients retreated with obefazimod in Phase 3 trial.

DarioHealth (DRIO) Expands Reach via Beluga Health Deal

  ()
DarioHealth (DRIO) integrates its AI platform with Beluga Health's network to scale provider-backed care. Discover growth catalysts, analyst targets, and investor considerations.